Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380907
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2022-11-15
Brief Title:
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
Sponsor:
Zai Lab Hong Kong Ltd
Organization:
Zai Lab Hong Kong Ltd
Study Overview
Official Title:
A Randomized Double-Blind Vehicle-Controlled Multicenter Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel A Human VH IL-17A Antibody Fragment in the Treatment of Chronic Plaque Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Randomized Double-Blind Vehicle-Controlled Multicenter Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel A Human VH IL-17A Antibody Fragment in the Treatment of Chronic Plaque Psoriasis
Detailed Description:
This is a randomized double-blind vehicle-controlled dose-ranging phase 2 study of ZL-1102 in patients with chronic plaque psoriasis Approximately 250 patients will be randomized at a ratio of 11111 to 5 treatment arms for 16 weeks of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None